Lymphocytes in Medical Technology
Navigation Links
Lymphocytes in Medical Technology
... directly cause their death.
The equivalent cell cycle defect is found in lymphocytes of people with
Alzheimer's. lymphocytes are white blood cells in the immune system that
can easily be collected ...
... immunity. In the United States, 85 percent of all cases of NHL come from B lymphocytes (B cells) and 15 percent from T lymphocytes (T cells). About 63,190 new cases of NHL will occur this year in the ...
... for the treatment of individuals with recent-onset type 1 diabetes, is a humanized monoclonal antibody engineered to alter the function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon ...
... course of four to 12 weeks. Beginning with the 0.1 mg/kg dose, evidence of biologic activity was observed. The median reduction in peripheral lymphocytes was 67% and was as high as 98%. Two patients with leukemia cutis had complete or partial clearance of skin lesions. One patient had a 36% reduction ...
... Following maturation, these dendritic cells activate Natural Killer (NK) and Natural Killer T-cells (NK-T) of the innate immune pathway and CD8+ lymphocytes of the adaptive immune pathway. Initiating the immune response in the GALT, and away from the tumor, reduces the effect of anti-immune factors ...
... DC2). Other parameters measured included mixed-leukocyte reaction (MLR), natural killer (NK) cell activity, the proliferative response of T lymphocytes toward mitogen (phytohemagglutinin [PHA]) and cytokine production of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, and (alpha)-tumor ...
... by the accumulation of functionally immature white blood cells (lymphocytes) in the bone marrow, blood, lymph tissue and other organs. Two types of lymphocytes are present in the blood, B cells and T cells. The majority of this patient population (90 percent) suffers from a subtype called B-cell chronic ...
... today results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Hodgkin's lymphoma (HL) as well as other CD30-expressing cancers. MDX-1401 demonstrated almost a doubling ...
... fully human antibody designed to target and inhibit the function of PD-1 (programmed cell death 1), a receptor expressed on the surface of activated lymphocytes (T-cells). The binding of PD-1 with one of two ligands (PD-L1 or PD-L2) is an important negative regulation pathway that suppresses or inhibits ...
... eventual commercialization of these vaccines. The second license agreement grants MabVax exclusive rights to the use of the licensed vaccines and lymphocytes from successfully vaccinated clinical trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline of fully ...
... the TNF family that is highly expressed on multiple cancers, including renal cell carcinoma, lymphoma and glioblastoma. CD70 expression on activated lymphocytes may also be implicated in autoimmune diseases. Data from the ongoing Phase 1 trial in clear cell renal carcinoma is expected in 2009. Additional ...
... fully human antibody designed to target and inhibit the function of PD-1 (programmed cell death 1), a receptor expressed on the surface of activated lymphocytes (T-cells) that is involved in the system of negative regulation for the suppression of activated lymphocytes. Preclinical studies suggest that ...
... AST (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), phosphorus decreased (18%) and triglycerides increased (44%). Strong inducers of CYP3A4/5 (e.g., ...
... AST (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), phosphorus decreased (18%) and triglycerides increased (44%). Strong inducers of CYP3A4/5 (e.g., ...
... of the GM-CSF transgene in cancer cells indicating effective gene delivery in vivo. Further, extensive tumor necrosis and tumor infiltrating lymphocytes (TILs) were observed within the tumors. Characterization of the recruited TILs showed CD35+ dendritic cells, CD8+ killer T cells, and CD138+ plasma B ...
... and analyze the data. About Ceplene Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen ...
... through Lexicon's gene knockout program, Genome5000(TM). Knockout mice lacking this enzyme had a significantly decreased number of circulating lymphocytes and were resistant to inflammation in a wide range of assays modeling processes involved in the development of arthritis and other autoimmune ...
... No findings were observed in clinical chemistry, hematology, coagulation or lymphocyte subpopulation measures except for a slight decrease in blood lymphocytes at the highest dose administered, and this effect could not be observed within one week after cessation of dosing. The histopathology results from ...
... decreased histopathological EAU scores compared to controls. In rats treated with either LX211 or CsA, antigen-specific and non-specific responses of lymphocytes to the protein used to induce EAU were diminished compared to those of the control group. "These positive preclinical results, combined with ...
... examined. ONTAK was granted accelerated approval in February 1999. CTCL is a rare disease in which certain cells of the lymph system known as T lymphocytes become cancerous and affect the skin. CTCL can progress to the lymph nodes, spleen, liver and other organs. About 10% of CTCL sufferers will ...
... and lymphomas are malignancies of lymphoid cells. Monoclonal antibodies, in addition to chemotherapy, have been shown to be effective in eliminating lymphocytes in leukemia and lymphoma patients (1,2,3,4). However, a significant number of patients relapse after initial responses and eventually become ...
... immunity. In the United States, 85 percent of all cases of NHL come from B lymphocytes (B cells) and 15 percent from T lymphocytes (T cells). About 63,190 new cases of NHL will occur this year in the ...
... for the treatment of individuals with recent-onset type 1 diabetes, is a humanized monoclonal antibody engineered to alter the function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon ...
... course of four to 12 weeks. Beginning with the 0.1 mg/kg dose, evidence of biologic activity was observed. The median reduction in peripheral lymphocytes was 67% and was as high as 98%. Two patients with leukemia cutis had complete or partial clearance of skin lesions. One patient had a 36% reduction ...
... Following maturation, these dendritic cells activate Natural Killer (NK) and Natural Killer T-cells (NK-T) of the innate immune pathway and CD8+ lymphocytes of the adaptive immune pathway. Initiating the immune response in the GALT, and away from the tumor, reduces the effect of anti-immune factors ...
... DC2). Other parameters measured included mixed-leukocyte reaction (MLR), natural killer (NK) cell activity, the proliferative response of T lymphocytes toward mitogen (phytohemagglutinin [PHA]) and cytokine production of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, and (alpha)-tumor ...
... by the accumulation of functionally immature white blood cells (lymphocytes) in the bone marrow, blood, lymph tissue and other organs. Two types of lymphocytes are present in the blood, B cells and T cells. The majority of this patient population (90 percent) suffers from a subtype called B-cell chronic ...
... today results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Hodgkin's lymphoma (HL) as well as other CD30-expressing cancers. MDX-1401 demonstrated almost a doubling ...
... fully human antibody designed to target and inhibit the function of PD-1 (programmed cell death 1), a receptor expressed on the surface of activated lymphocytes (T-cells). The binding of PD-1 with one of two ligands (PD-L1 or PD-L2) is an important negative regulation pathway that suppresses or inhibits ...
Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
... increased the production of West Nile Virus-specific IgM, IgG and T cells in young mice. Producing higher levels of these critical antibodies and lymphocytes is essential in helping the immune system protect itself from infection. AHCC also had an effect in aged mice but it was not as strong as on young ...... eventual commercialization of these vaccines. The second license agreement grants MabVax exclusive rights to the use of the licensed vaccines and lymphocytes from successfully vaccinated clinical trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline of fully ...
Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
... the United States. Approximately 4,000 people in this country are expected to die of CLL during 2008. (3) CLL, which involves production of abnormal lymphocytes (white blood cells) starts in the bone marrow and can spread through the blood to the lymph nodes, spleen, liver and other parts of the body. (3) ...... the TNF family that is highly expressed on multiple cancers, including renal cell carcinoma, lymphoma and glioblastoma. CD70 expression on activated lymphocytes may also be implicated in autoimmune diseases. Data from the ongoing Phase 1 trial in clear cell renal carcinoma is expected in 2009. Additional ...
... fully human antibody designed to target and inhibit the function of PD-1 (programmed cell death 1), a receptor expressed on the surface of activated lymphocytes (T-cells) that is involved in the system of negative regulation for the suppression of activated lymphocytes. Preclinical studies suggest that ...
... AST (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), phosphorus decreased (18%) and triglycerides increased (44%). Strong inducers of CYP3A4/5 (e.g., ...
... AST (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), phosphorus decreased (18%) and triglycerides increased (44%). Strong inducers of CYP3A4/5 (e.g., ...
... of the GM-CSF transgene in cancer cells indicating effective gene delivery in vivo. Further, extensive tumor necrosis and tumor infiltrating lymphocytes (TILs) were observed within the tumors. Characterization of the recruited TILs showed CD35+ dendritic cells, CD8+ killer T cells, and CD138+ plasma B ...
... and analyze the data. About Ceplene Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen ...
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
... AST (38%), and leukopenia (32%). Most common grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), phosphorus decreased (18%), and triglycerides increased (44%). Strong inducers of CYP3A4/5 (eg, ...St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases
... 1 diabetes; and for inflammatory diseases, such as inflammatory bowel disease and asthma. The St. Jude team discovered that specialized immune lymphocytes called regulatory T cells release a protein complex composed of two proteins called Ebi3 and Il12a. This complex acts like a brake on the activity ...... through Lexicon's gene knockout program, Genome5000(TM). Knockout mice lacking this enzyme had a significantly decreased number of circulating lymphocytes and were resistant to inflammation in a wide range of assays modeling processes involved in the development of arthritis and other autoimmune ...
EpiCept Reports Regulatory Progress on Ceplene(TM)
... the first half of 2008. About Ceplene Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen ...ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
... Administered shortly following radiation exposure, Radilex was able to subsequently increase circulating levels of monocytes, granulocytes and lymphocytes in all treated animals. "The results of this study have strengthened our confidence that Radilex(TM) may prove to be a life saving treatment ...... No findings were observed in clinical chemistry, hematology, coagulation or lymphocyte subpopulation measures except for a slight decrease in blood lymphocytes at the highest dose administered, and this effect could not be observed within one week after cessation of dosing. The histopathology results from ...
Data to be presented at AAN Meeting -Study results of drug candidate for MS
... to bind to the sphingosine 1-phosphate receptor-1 (S1P-R1) on circulating lymphocytes (white blood cells). This activity reversibly traps a proportion of lymphocytes in the lymph nodes, reducing the number of inflammatory T-cells ...... decreased histopathological EAU scores compared to controls. In rats treated with either LX211 or CsA, antigen-specific and non-specific responses of lymphocytes to the protein used to induce EAU were diminished compared to those of the control group. "These positive preclinical results, combined with ...
... examined. ONTAK was granted accelerated approval in February 1999. CTCL is a rare disease in which certain cells of the lymph system known as T lymphocytes become cancerous and affect the skin. CTCL can progress to the lymph nodes, spleen, liver and other organs. About 10% of CTCL sufferers will ...
... and lymphomas are malignancies of lymphoid cells. Monoclonal antibodies, in addition to chemotherapy, have been shown to be effective in eliminating lymphocytes in leukemia and lymphoma patients (1,2,3,4). However, a significant number of patients relapse after initial responses and eventually become ...
Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
... production of the protein Bcl-2 and its beneficial effects in patients are thought to be due to the drug reducing Bcl-2 levels within cancerous CLL lymphocytes by binding specifically to and inactivating the messenger RNA for Bcl-2. High levels of Bcl-2 in CLL cells are associated with resistance to cancer ...Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
... usually advisable for confirmation. Serologic findings include a normal to moderately elevated white blood cell count, an increased total number of lymphocytes and greater than 10 percent atypical lymphocytes. In keeping with the rapid proliferation of point-of-care diagnostic kits and devices, several ...Other ContentsprotocellsprotonsprotonsprotonsprotonsprotoproximalproximalproximalproximalproximalproximalproximalproximalregionsregionsregionsregionsregionsregionsregionsregionsregionspseudoautosomalOther TagsTNFColumnsColumnsNovascreenFractionFractionGFPOther Tagsradiologist 2radiologist 3multiplication 2social 2social 3social 4social 5social 6social 7social 8social 9social 10form 2form 3form 4form 5form 6form 7form 8form 9form 10sounds 2sounds 3sounds 4
(Date:11/23/2009)...unprecedented detail how the ribosome interacts wi...ide them toward their destination in biological ce...fitting (MDFF) to examine the interaction of the r... The first study, in Proceedings of the National...ling between the ribosome and an elongation factor...
(Date:11/23/2009)...ries about the multiple health benefits of vitamin...ient, increased awareness of the huge numbers of p...d even led to an appreciation of it as "nature,s a...of your immune system to prevention of heart disea...is now seen as one of the most critical nutrients ...
(Date:11/23/2009)... , , , , , , , ... Marshall, from the Environment Department at the ...nyongia magomberae and his wider work in Tanzania...tion. , , , , , , , ..., , , , A new species of chameleon has be...
Breaking Biology News(10 mins):Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Integrated Medical Systems Receives 243 25 Million from the U S Army for Worlds First Suitcase Intensive Care Unit 54144 1Integrated Medical Systems Receives 243 25 Million from the U S Army for Worlds First Suitcase Intensive Care Unit 54144 2Integrated Medical Systems Receives 243 25 Million from the U S Army for Worlds First Suitcase Intensive Care Unit 54144 3Spectrum Announces New Distribution of AC Powered Tool for Crimping and Decapping of Laboratory Vials The CRIMPenstein 26amp 3B 238482 3B 13482 1Spectrum Announces New Distribution of AC Powered Tool for Crimping and Decapping of Laboratory Vials The CRIMPenstein 26amp 3B 238482 3B 13482 2EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 1EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 2EyeCare America Works to Prevent Blindness Caused by Cataracts 54141 3(Date:11/25/2009)...ological symptoms, study finds , , WEDN...de effects are among the potential problems faced ...re treated with cisplatin-based chemotherapy, a ne...orwegian men treated for unilateral testicular can...w-up survey conducted from 1998 to 2002. , The ...
(Date:11/25/2009)...Newswire-USNewswire/--TheAmericanAssociationforHom...9,"S.2128,whichisdesignedtosubstantiallyimprovetoo...ebillwasintroducedbySen.GeorgeLeMieux(R-Fla.). ,...canAssociationforHomecareoutlinedinits13-pointanti...ressinFebruary.Thoseprovisionsincludecallingforrea...
(Date:11/25/2009)...al cancer also can reverse a rare stomach disorder...he disease, researchers at Vanderbilt University M...se causes thickening of the stomach lining, severe...nemia and swelling in the feet and ankles due to p...stric cancer. Previously, the only effective treat...
(Date:11/25/2009)...sh that mimicked parts of speech colored perceptio...thDay News) -- People can "hear" not only with the...ows. , In fact, sensations on the skin designed...people decipher sounds better, the Canadian scient...whether we could use tactile information in this w...
(Date:11/25/2009)...ace.com, the premier resource for life science car...f the BioForest™ Hotbed Campaign this mornin...) November 25, 2009 -- BioSpace.com, the premier r...unveiled the third edition of the BioForest™...nal campaign is a promotional effort highlighting ...
Breaking Medicine News(10 mins):Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2[0] Long-Term Problems Linked to Testicular Cancer Chemo[1] American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009'[1] Vanderbilt scientists report first effective medical therapy for rare stomach disorder[0] Your Skin Can Help Your Ears Listen [1] BioSpace Showcases Leading Life-Science Companies in the Northwest
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |